Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens

Anti-cancer Drugs
Gudrun WürthweinJoachim Boos

Abstract

Pharmacokinetics after high-dose (HD) etoposide (Eto) (40 mg/kg i.v. once as 4-h infusion, one patient 20 mg/kg i.v. as 4-h infusion, for 3 consecutive days) were studied in 31 children and young adults (age 0.8-23.7 years, median: 8.0 years) undergoing bone marrow transplantation after different conditioning regimens. Blood samples were collected until 97 h after the end of infusion. The population analysis of the first part of data (112 samples/21 patients, well documented) served to establish the pharmacokinetic model. The same data combined with the second part of data (50 samples/10 patients, 'intention to treat') then served to calculate the final population model. Data were best described by a three-compartment model with t1/2alpha = 0.28 h +/- 3.2%, t1/2beta = 3.6 h +/- 16.9% and t1/2gamma = 44.2 h +/- 56.5%, respectively (mean(geom) +/- CV(geom)). Clearance (CL) was 15.5 ml/min/m2 +/- 30.6% (mean(geom) +/- CV(geom)) and thus at the lower range of data reported in the literature. The fraction of unbound Eto (fu) was 7.0% (4.3-11.9%) [median (range)], with high intra-individual variability. An increase in f(u) with increasing total Eto was observed. The question of a principally lower Eto CL in children, as compared to a...Continue Reading

References

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·P KöhlH Jungclas
Jun 1, 1992·Clinical Pharmacology and Therapeutics·T MaddenJ H Rodman
Oct 1, 1991·Clinical Pharmacology and Therapeutics·C F StewartW E Evans
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C F StewartW E Evans
Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L SlevinP F Wrigley
Jan 1, 1989·Clinical Pharmacology and Therapeutics·C F StewartW E Evans
May 1, 1988·Clinical Pharmacology and Therapeutics·E M NewmanK G Blume
Oct 1, 1986·European Journal of Cancer & Clinical Oncology·J J HolthuisN H Mulder
Jan 1, 1985·Clinical and Laboratory Haematology·T J LittlewoodD P Bentley
Oct 1, 1985·British Journal of Cancer·R Bailey-WoodD P Bentley
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·B LiuD J Kerr
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H RodmanV M Santana
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K MrossD K Hossfeld
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·T L SchwinghammerC F Stewart
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BoosH Jürgens
Mar 1, 1997·Journal of Biopharmaceutical Statistics·L F LaceyA Bye
Jan 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K MrossA Zander
Jan 27, 1998·Cancer Chemotherapy and Pharmacology·L NguyenP Canal
Sep 23, 1998·Klinische Pädiatrie·B TillmannJ Boos
Jan 29, 1999·European Journal of Clinical Pharmacology·N PerdaemsE Chatelut

❮ Previous
Next ❯

Citations

Feb 3, 2011·European Journal of Clinical Pharmacology·Francesco BellantiOscar Della Pasqua
Jul 27, 2011·Cancer Chemotherapy and Pharmacology·Gisela KerstingGeorg Hempel
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gareth J VealClinton F Stewart
Dec 12, 2012·British Journal of Clinical Pharmacology·Johan G C van HasseltAlwin D R Huitema
Aug 31, 2012·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Gautam BahetiBruce B Gordon
Jul 27, 2015·Seminars in Oncology Nursing·Andrew J BukowinskiMaureen M O'Brien
Jun 7, 2007·Journal of Pediatric Hematology/oncology·Stefano FerrariPiero Picci
Jul 10, 2008·Clinical Pharmacokinetics·Anthe S ZandvlietAlwin D R Huitema
Jan 28, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Takako KatoYoshinobu Takakura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.